Zhang Bin, Shi Wei, He Chao-sheng, Liang Xing-ling, Liu Shuang-xin, Liang Yong-zheng
Department of Nephrology, Guangdong General Hospital, Southern Medical University, Guangzhou 510080, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1272-4, 1278.
To evaluate the clinical efficacy of continuous venous-venous hemofiltration (CVVH) combined with coupled plasma filtration adsorption (CPFA) in the management of systemic inflammation response syndrome (SIRS) complicated by acute renal failure (ARF).
Thirty patients with SIRS complicated by ARF (including 25 with severe acute pancreatitis, 2 with colonic perforation with infection, and 3 with acute infective endocarditis) were randomly divided into CVVH plus CPFA group (n=14) and CVVH alone group (n=16). The APACHE II score, mean arterial pressure, PaO2/FiO2, TNF-alpha and IL-10 were detected prior to or after the intervention. The feasibility and tolerance of CVVH plus CPFA and the therapy-related adverse reactions were evaluated.
The two groups showed no significant differences in the baseline clinical characteristics (P>0.05). The mean arterial pressure and PaO2/FiO2 increased significantly after treatment as compared with the control (P<0.05), with TNF-alpha being reduced and IL-10 elevated. In CVVH plus CPFA group, APACHEII score improved significantly after 10 days (P<0.05). No therapy-related adverse reactions were noted, suggesting good tolerance of CVVH plus CPFA.
CVVH combined with CPFA is an effective and safe method for improving the clinical outcome of patients with SIRS and ARF.
评估持续静脉-静脉血液滤过(CVVH)联合配对血浆滤过吸附(CPFA)治疗全身炎症反应综合征(SIRS)合并急性肾衰竭(ARF)的临床疗效。
30例SIRS合并ARF患者(包括25例重症急性胰腺炎、2例结肠穿孔伴感染、3例急性感染性心内膜炎)随机分为CVVH联合CPFA组(n = 14)和单纯CVVH组(n = 16)。在干预前后检测急性生理与慢性健康状况评分系统II(APACHE II)评分、平均动脉压、氧合指数(PaO2/FiO2)、肿瘤坏死因子-α(TNF-α)和白细胞介素-10(IL-10)。评估CVVH联合CPFA的可行性和耐受性以及治疗相关不良反应。
两组基线临床特征无显著差异(P>0.05)。与对照组相比,治疗后平均动脉压和氧合指数显著升高(P<0.05),TNF-α降低,IL-10升高。CVVH联合CPFA组在治疗10天后APACHE II评分显著改善(P<0.05)。未观察到治疗相关不良反应,提示CVVH联合CPFA耐受性良好。
CVVH联合CPFA是改善SIRS合并ARF患者临床结局的一种有效且安全的方法。